ANTONUZZO, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.249
EU - Europa 2.189
AS - Asia 741
OC - Oceania 3
SA - Sud America 3
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.187
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.243
IT - Italia 616
IE - Irlanda 530
PL - Polonia 408
HK - Hong Kong 381
SE - Svezia 266
JO - Giordania 127
CN - Cina 113
RU - Federazione Russa 70
CH - Svizzera 58
GB - Regno Unito 57
DE - Germania 54
IN - India 50
AT - Austria 44
SG - Singapore 32
VN - Vietnam 22
FI - Finlandia 17
UA - Ucraina 17
FR - Francia 16
ES - Italia 10
BE - Belgio 8
NL - Olanda 7
CA - Canada 6
TW - Taiwan 5
AU - Australia 3
BR - Brasile 3
GR - Grecia 3
NO - Norvegia 3
TR - Turchia 3
HR - Croazia 2
IR - Iran 2
LK - Sri Lanka 2
MY - Malesia 2
BY - Bielorussia 1
DK - Danimarca 1
EG - Egitto 1
EU - Europa 1
JP - Giappone 1
RO - Romania 1
TH - Thailandia 1
Totale 5.187
Salva come PNG Salva come JPEG
Città #
Dublin 525
Warsaw 406
Fairfield 279
Chandler 270
Hong Kong 269
Ashburn 262
Seattle 116
Woodbridge 110
Wilmington 105
Cambridge 101
Lawrence 101
Altamura 92
Florence 86
Houston 86
Moscow 64
Princeton 61
Bern 57
Ann Arbor 55
Boston 50
Pune 48
Shanghai 46
Vienna 44
Beijing 43
Milan 39
Rome 35
New York 34
Buffalo 33
San Diego 29
Boardman 27
London 20
Singapore 19
Dong Ket 18
Bremen 16
Medford 15
Jacksonville 14
Brescia 12
Naples 12
Barcelona 10
Helsinki 10
Krefeld 10
Hillsboro 9
Norwalk 9
Washington 8
Brussels 7
Falls Church 7
Paris 7
Redwood City 7
Bologna 6
Pescara 6
Arezzo 5
Chicago 5
Hangzhou 5
Modena 5
Perugia 5
Prad am Stilfser Joch 5
Prescot 5
Shenzhen 5
Siena 5
Toronto 5
Trento 5
Amandola 4
Changsha 4
Freiburg im Breisgau 4
Palermo 4
Parma 4
Recanati 4
Trevignano 4
Turin 4
Udine 4
Alba 3
Amsterdam 3
Andover 3
Bari 3
Francavilla al Mare 3
Genoa 3
Gradignan 3
Laurel 3
Livorno 3
Lucca 3
Monte Porzio Catone 3
Mykolayiv 3
Nanjing 3
Oslo 3
Vico Equense 3
Ancona 2
Aprilia 2
Archanes 2
Argelato 2
Bacoli 2
Bergamo 2
Brusaporto 2
Campi Bisenzio 2
Canegrate 2
Carmignano 2
Chennai 2
Cinisello Balsamo 2
Civitella del Tronto 2
Clarkston 2
Colombo 2
Conversano 2
Totale 3.863
Salva come PNG Salva come JPEG
Nome #
HERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy 227
Gallbladder neuroendocrine neoplasm: a case report and critical evaluation of WHO classification 162
Adjuvant chemotherapy in completely resected gastric cancer: A randomized phase III trial conducted by GOIRC 140
SURVIVAL AND PROGNOSTIC FACTORS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED BY PERCUTANEOUS ETHANOL INJECTION: A 10-YEAR EXPERIENCE. 110
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study 110
hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients 102
Metastatic intracranial solitary fibrous tumors/hemangiopericytomas: description of two cases with radically different behaviors and review of the literature 95
Analysis and optimization of clinical pathway of a cancer patient in a University Hospital 92
Single-stage operation using hypothermic circulatory arrest to remove uterine intravenous leiomyomatosis extended to the vena cava and right atrium 88
Circulating tumour cells in colorectal cancer 86
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 86
Skin metastasis from typical carcinoid tumor of the lung. 85
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect 85
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report 81
KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation 80
Regorafenib also can cause osteonecrosis of the jaw 80
Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib 72
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues 65
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors 63
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience 61
A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy 60
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: The Colon Life nomogram 57
Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA–PEG nanoparticles 57
Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: A real-world analysis 57
Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis 52
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer 51
A multi-center study on the surgical management of metastatic disease to adrenal glands 51
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 50
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors 50
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 50
Bevacizumab in non-small cell lung cancer 49
Detection of PIK3CA E545A mutation in circulating tumor DNA of a patient affected by uterine carcinosarcoma 49
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial 49
Chasing the target: New phenomena of resistance to novel selective ret inhibitors in lung cancer. updated evidence and future perspectives 49
Induction chemotherapy followed by pleurectomy decortication and hyperthermic intraoperative chemotherapy (Hithoc) for early-stage epitheliod malignant pleural mesothelioma—a prospective report 47
Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study 46
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 44
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 44
Occurrence of Dysgeusia in Patients Being Treated for Cancer 44
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 43
Immune checkpoint inhibitors in the treatment of renal cancer: Current state and future perspective 43
Everolimus in pancreatic neuroendocrine carcinomas G3 43
Mutational profile in circulating tumor DNA in a patient affected by low-risk endometrial cancer: Predictable tool of relapse? 43
Active therapy or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The BEYOND study (Meet-Uro 19) 42
Real-world study of everolimus in advanced progressive neuroendocrine tumors 41
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy 41
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study 40
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 40
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 38
Skin metastasis from typical carcinoid tumor of the lung 38
Body composition parameters predict pathological response and outcomes in locally advanced gastric cancer after neoadjuvant treatment: A multicenter, international study 38
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy 36
Growth arrest-specific 5 lncRNA as a valuable biomarker of chemoresistance in osteosarcoma 35
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study) 34
Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET 33
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study 33
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 31
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma 31
Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies 31
Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study 31
Alteration of the Nucleotide Excision Repair (NER) Pathway in Soft Tissue Sarcoma 30
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 29
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours 29
Soft tissue sarcoma: An insight on biomarkers at molecular, metabolic and cellular level 29
Treatment Strategy for Oligometastatic Gastric Cancer: Brief Considerations 29
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 29
Liquid biopsy in colorectal cancer: No longer young, but not yet old 28
Results of the observational prospective RealFLOT study 28
Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors 28
Metastatic gastric cancer in the last two decades: Goals achieved and future promises 28
Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity 28
Primary pleural epithelioid hemangioendothelioma: case report and review of the literature 28
Gender matters. Sex-related differences in immunotherapy outcome in patients with non-small cell lung cancer 27
Current status and future perspectives in HER2 positive advanced gastric cancer 27
In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations" 27
Analysis of molecular and clinical markers of resistance to bacillus of Calmette-Guérin immunotherapy in patients with urothelial non-muscle invasive bladder cancer 26
Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes 26
Isoforms of the orphan nuclear receptor COUP-TFII differentially modulate pancreatic cancer progression 26
Somatostatin analogs in pregnant patients with neuroendocrine tumor 26
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial 26
Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification 25
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment 24
Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy 24
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice 24
ROS1 rearrangements are uncommon in biliary tract cancers 23
Systemic Sclerosis Association with Malignancy 23
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation 22
The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane-derived, and platinum-based drugs 22
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 22
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions 21
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards 21
Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study 21
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research 21
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough 21
Response 20
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors 20
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma 19
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience 19
Robotic approach with neoadjuvant chemotherapy in adult Wilms' tumor: A feasibility study report and a systematic review of the literature 19
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 19
Totale 4.695
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.990
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.990
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019105 0 0 0 0 0 0 0 0 0 21 45 39
2019/2020439 22 19 9 23 30 40 36 46 44 35 122 13
2020/2021703 69 47 40 111 44 54 37 64 60 87 55 35
2021/2022461 9 33 45 13 18 12 13 65 34 22 69 128
2022/20232.132 103 285 67 153 109 413 301 272 237 31 78 83
2023/20241.513 39 98 168 136 117 272 115 398 68 102 0 0
Totale 5.491